medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2013-11-82-87medsovet-1152Research ArticleПрактикаPracticeМоксифлоксацин: фокус на профиль безопасностиMoxifloxacin: safety profileСинопальниковА. И.SinopalnikovA. I.noemail@neicon.ruРоссийская медицинская академия последипломного образования, МоскваРоссияRussian Medical Academy of Postgraduate Education, Moscow Moxifloxacin: safety profileRussian Federation2013301220130118287Copyright © Синопальников А.И., 20132013Синопальников А.И.Sinopalnikov A.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1152

Сегодня новые, или так называемые респираторные, фторхинолоны относятся к одной из групп антимикробных препаратов (АМП), наиболее часто назначаемых по такому актуальному в повседневной клинической практике показанию, как внебольничные инфекции нижних дыхательных путей (вИНДП).

The latest, so-called respiratory, fluoroquinolones are a group of antimicrobial agents (AMA), most commonly prescribed for community-acquired lower respiratory tract infection (caLRTI), which is a relevant issue in routine clinical practice.

респираторные фторхинолоныинфекции нижних дыхательных путеймоксифлоксацинбезопасностьrespiratory fluoroquinoloneslower respiratory tract infectionsmoxifloxacinsafetyReferencesOwens R., Ambrose P. Clinical use of the fluoroquinolones // Med. Clin. North. Am. 2000. №84. P. 1447–1469.Owens R., Ambrose P. Clinical use of the fluoroquinolones // Med. Clin. North. Am. 2000. №84. P. 1447–1469.Bolon M.K. The newer fluoroquinolons // Med. Clin. North. Amer. 2011. №95. P. 793–817.Bolon M.K. The newer fluoroquinolons // Med. Clin. North. Amer. 2011. №95. P. 793–817.Ball P. The quinolones: history and overview. In: Andriole VT, editor. The quinolones. Third edition. San Diego //Ball P. The quinolones: history and overview. In: Andriole VT, editor. The quinolones. Third edition. San Diego //Academic Press. 2000. P. 1–33.Academic Press. 2000. P. 1–33.O’Donnell J.A., Gelone S.P. The newer fluoroquinolones // Infect. Dis. Clin. North. Amer. 2004. №18. P. 691–716.O’Donnell J.A., Gelone S.P. The newer fluoroquinolones // Infect. Dis. Clin. North. Amer. 2004. №18. P. 691–716.Yuan X., Liang B.-B., Wang R. et al. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials // J. Chemother. 2012. №24. P. 257–267.Yuan X., Liang B.-B., Wang R. et al. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials // J. Chemother. 2012. №24. P. 257–267.Mandell L.A., Wunderink R.G., Anzueto A. et al. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults // Clin. Infect. Dis. 2007. №44Mandell L.A., Wunderink R.G., Anzueto A. et al. Infectious diseases society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults // Clin. Infect. Dis. 2007. №44(Suppl. 2). P. 27–72.(Suppl. 2). P. 27–72.Woodhead M., Blasi F., Ewig S. and the ERS/ESCMID. Task Force. Guidelines for the management of adult lower respiratory tract infections // Clin. Microbiol. Infect. 2011. №17. P. 1–59.Woodhead M., Blasi F., Ewig S. and the ERS/ESCMID. Task Force. Guidelines for the management of adult lower respiratory tract infections // Clin. Microbiol. Infect. 2011. №17. P. 1–59.Чучалин А.Г., Синопальников А.И., Козлов Р.С. и соавт. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике // Клин. микробиол. и антимикроб. химиотер. 2010.№12(3). P. 186–226.Чучалин А.Г., Синопальников А.И., Козлов Р.С. и соавт. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике // Клин. микробиол. и антимикроб. химиотер. 2010.№12(3). P. 186–226.Andriole V.T. The quinolones: past, present, and future // Clin. Infect. Dis. 2005. №41 (Suppl. 2). P. 113–119.Andriole V.T. The quinolones: past, present, and future // Clin. Infect. Dis. 2005. №41 (Suppl. 2). P. 113–119.Ball P. Adverse drug reactions: Implications for the fluoroquinolones // J. Antimicrob. Chemother. 2003. №51 (Suppl.1). P. 21–27.Ball P. Adverse drug reactions: Implications for the fluoroquinolones // J. Antimicrob. Chemother. 2003. №51 (Suppl.1). P. 21–27.Drugs@FDA page. Available at: http//www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed April 18,2011.Drugs@FDA page. Available at: http//www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed April 18,2011.Available at: http//www.infectweb.com.Available at: http//www.infectweb.com.Kubin R., Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. 41st ICAAC, Sept. 2000, Toronto. Canada, Abst. 820.Kubin R., Reiter C. Safety update of moxifloxacin: a current review of clinical trials and post-marketing observational studies. 41st ICAAC, Sept. 2000, Toronto. Canada, Abst. 820.Ball A.P. The Quinolones – history and overview. In: The Quinolones, 3rd Edition. Ed VT Andriole. San Diego, USA. Academic Press, 2001. Chap.1.Ball A.P. The Quinolones – history and overview. In: The Quinolones, 3rd Edition. Ed VT Andriole. San Diego, USA. Academic Press, 2001. Chap.1.Ball P., Stahlmann R., Kubin R. et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies // Clin. Ther. 2004. №26. P. 940–950.Ball P., Stahlmann R., Kubin R. et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies // Clin. Ther. 2004. №26. P. 940–950.Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of safety profile of oral moxofloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28: 443-452.Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of safety profile of oral moxofloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28: 443-452.Iannini PB, Kubin R, Reiter C. Over 10 million patient uses: an update on the safety profile of oral moxifloxacin.Iannini PB, Kubin R, Reiter C. Over 10 million patient uses: an update on the safety profile of oral moxifloxacin.Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, USA(2002) (Poster L-374).Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Diego, USA(2002) (Poster L-374).Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. An analysis of 14 years of clinical data. Drugs R D 2012; 12: 71-100.Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety. An analysis of 14 years of clinical data. Drugs R D 2012; 12: 71-100.Owens RC, Ambrose PG. Atnimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl. 2): S144- S157.Owens RC, Ambrose PG. Atnimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41 (Suppl. 2): S144- S157.Avelox® 400 mg film-coated tablets. Summary of product characteristics. Bayer Healthcare Pharmaceuticals Inc.,Leverkusen, Germany, Revised March 2008Avelox® 400 mg film-coated tablets. Summary of product characteristics. Bayer Healthcare Pharmaceuticals Inc.,Leverkusen, Germany, Revised March 2008Veyssier P, Voirot P, Begaud B, et al. Cardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (IMMEDIAT study)[in French]. Med Mal Infect 2006; 36: 505-512.Veyssier P, Voirot P, Begaud B, et al. Cardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (IMMEDIAT study)[in French]. Med Mal Infect 2006; 36: 505-512.US Avelox® package insert [online]. Available from URL: http://www.univgraph.com/bayer/inserts/avelox.pdf [Accessed 2009 March 18].US Avelox® package insert [online]. Available from URL: http://www.univgraph.com/bayer/inserts/avelox.pdf [Accessed 2009 March 18].Haverkamp W, Kruesmann F, Fritsch A, et al. Update on the cardiac safety of moxifloxacin. Current Drug Safety 2012; 7: 149-163.Haverkamp W, Kruesmann F, Fritsch A, et al. Update on the cardiac safety of moxifloxacin. Current Drug Safety 2012; 7: 149-163.Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organization. Drug Saf 2007; 30: 705-713.Johannes CB, Ziyadeh N, Seeger JD, et al. Incidence of allergic reactions associated with antibacterial use in a large, managed care organization. Drug Saf 2007; 30: 705-713.Dhalla IA, Mamdani MM, Simor AE, et al. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antomicrob Agents Chemother 2006; 50: 3216-3219.Dhalla IA, Mamdani MM, Simor AE, et al. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Antomicrob Agents Chemother 2006; 50: 3216-3219.EMEA. Annex II. The scientific conclusions and the grounds for amendments of the summary of product characteristics and package leaflet. December 2008. http://www.ec.europa.eu/enterprise/pharmaceuticals/ register/refh_others.htmEMEA. Annex II. The scientific conclusions and the grounds for amendments of the summary of product characteristics and package leaflet. December 2008. http://www.ec.europa.eu/enterprise/pharmaceuticals/ register/refh_others.htmAndrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.Salvo F, Polimeni G, Moretti U, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 2007; 60: 121-126.Salvo F, Polimeni G, Moretti U, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemother 2007; 60: 121-126.van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359-378.van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32: 359-378.

The authors declare that there are no conflicts of interest present.